Tamtam Try Tamtam free
Bausch + Lomb logo

Bausch + Lomb account plan

Global eye health products

At a glance

Bausch + Lomb is an eye health company with about 400 products, $5,101 million FY2025 revenue and approximately 13,000 employees.

Bausch + Lomb is a fully integrated eye health business selling contact lenses, lens care, eye vitamins, prescription eye medications, intraocular lenses and surgical systems through direct sales forces and distributors. Headquartered in Vaughan, Ontario, it has approximately 13,000 employees, a presence in approximately 100 countries and 25 manufacturing facilities in 11 countries. FY2025 revenue was $5,101 million (+6%), with operating income of $113 million and a net loss attributable of $360 million. It is listed on the NYSE and TSX (BLCO) and Bausch Health held approximately 87% of the shares as of October 21, 2026, while it continues to evaluate completing the Separation.

Business units

Strategic priorities

Vision 27 three-year plan
Interim CEO Thomas J. Appio's priorities are improving profitability, meeting or exceeding the three-year plan targets and advancing the pipeline. The 2028 target is a 23% adjusted EBITDA margin.
Deleveraging
Net leverage was 4.1x in Q3 2026 versus 5.7x a year earlier, with a target of 3.5x or better by end-2028; management calls delevering the highest priority.
SG&A savings and margin expansion
Appio said there are opportunities to drive SG&A savings; the CFO cited product mix, network optimization and vertical integration for gross margin, and about 150 basis points of SG&A improvement year to date.
Pipeline and premium products
Launches planned include ELIOS (U.S. by end-2026), SeeLyra (510k approval anticipated by end-2026), enVista Beyond EDOF (U.S. launch 2027), Lumify NXT (approval anticipated H1 2027) and a myopia-control lens study starting in Q4 2026.
Settling ownership
Bausch Health continues to evaluate completing the Separation, which may be a monetization of its stake, a sale, a distribution to its shareholders or a combination.

Latest results

In Q3 2026 revenue was $1.375 billion versus $1.281 billion, up 7% (about 8% at constant currency), with growth in all three segments. Adjusted EBITDA rose to $325 million from $243 million, a 23.6% margin, and net income attributable was $32 million versus a $28 million loss. Operating cash flow was $233 million and free cash flow $178 million, which the CFO called the strongest quarter of cash generation since the IPO. Nine-month revenue was $4,013 million, up 9%. Full-year 2026 guidance was raised for the third time to revenue of $5.450-5.550 billion and adjusted EBITDA excluding acquired IPR&D of $1.090-1.140 billion.

Investments and deals

Recent acquisitions
Whitecap Biosciences (January 2025) and a manufacturing facility in Mexico (December 2025), after Elios Vision and Trukera Medical (2024) and XIIDRA, Blink and AcuFocus (2023); XIIDRA cost a $1,750 million upfront payment.
Capital expenditure
Capex of about $285 million is guided for 2026, after higher capex drove a $455 million investing outflow in 2025.
Refinancing
A June 2025 package (an $800 million revolver, a $2,325 million term B loan and €675 million secured notes) was followed by a $2,802 million refinancing term loan due January 2031 in January 2026.
Digital and AI
Orphia is an AI-powered digital health platform for eye care providers, and the company launched the Bausch + Lomb AI Academy for employees in 2025.

Challenges and risks

High indebtedness
Interest expense was $421 million in FY2025 and is guided at about $365 million for 2026; corporate ratings are in the B range.
Gross-to-net pressure
Provisions reached 40.6% of gross product sales in Q3 2026, mainly from rebates on XIIDRA and MIEBO, and FY2025 net pricing cut revenue by $53 million.
Quality and manufacturing compliance
The March 2025 enVista recall hit Surgical profit, and the Tampa, Florida plant received an FDA warning letter in September 2026, though the company expects no supply interruption.
Tariffs and policy
Tariffs raised cost of goods sold in 2025, and a U.S. proclamation imposes a 100% tariff on patented pharmaceutical products, with exemptions.
Leadership and ownership uncertainty
Brent Saunders left on October 12, 2026; the interim CEO also runs Bausch Health, which the 10-Q lists as a source of competing demands and possible conflicts of interest.

What leadership says

“Our third-quarter performance reflects the strength and breadth of the business, with growth across all three segments and continued expansion in profitability”

Thomas J. Appio, Chairman and Interim CEO · Q3 2026 results release, 28 October 2026

“We have to reduce our debt.”

Thomas J. Appio, Chairman and Interim CEO · Q3 2026 earnings call, 28 October 2026

“we're not sacrificing innovation for metrics.”

Brent Saunders, former Chairman and CEO · Q2 2026 earnings call, 29 July 2026

“delevering is our highest priority”

Brent Saunders, former Chairman and CEO · Q2 2026 earnings call, 29 July 2026

Where a supplier can help

SG&A efficiency
The interim CEO's push for SG&A savings across selling, advertising and G&A opens doors for vendors that lower commercial or back-office cost per sale.
Manufacturing network and quality
Network optimization, vertical integration, the new Mexico facility and the Tampa FDA warning letter point to needs in quality systems, compliance and manufacturing automation.
Tariff and supply chain resilience
Tariff exposure and single-source products make supply chain planning, trade compliance and second-source manufacturing relevant.
Launch support for the pipeline
ELIOS, SeeLyra, enVista Beyond and Lumify NXT launches need surgeon and eye care professional education, field enablement and market access support.
Digital and AI programmes
Orphia and the AI Academy indicate demand for data, AI and digital health partners aligned with the Vision 27 plan.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Bausch + Lomb?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Bausch + Lomb

What does Bausch + Lomb do?

It is an eye health company with about 400 products across Vision Care (contact lenses and consumer eye care), Pharmaceuticals (eye medications such as XIIDRA and MIEBO) and Surgical (cataract, vitreoretinal and refractive systems and implants).

What is Bausch + Lomb's revenue?

FY2025 revenue was $5,101 million, up 6%. Q3 2026 revenue was $1.375 billion, and 2026 guidance is $5.450-5.550 billion.

How many employees does Bausch + Lomb have?

Approximately 13,000, with a presence in approximately 100 countries, according to the FY2025 10-K.

Who leads Bausch + Lomb?

Thomas J. Appio has been chairman and interim CEO since October 12, 2026, while remaining CEO of Bausch Health; Osama (Sam) Eldessouky is CFO.

Who owns Bausch + Lomb?

Bausch Health held approximately 87% of the shares as of October 21, 2026 and continues to evaluate completing the Separation.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)